JOYO PHARMA
Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.
JOYO PHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2017-01-01
Address:
Guangzhou, Guangdong, China
Country:
China
Status:
Active
Total Funding:
300 M CNY
Investors List
Sequoia Capital China
Sequoia Capital China investment in Series B - Joyo Pharma
SDIC Venture Capital
SDIC Venture Capital investment in Series B - Joyo Pharma
More informations about "Joyo Pharma"
Joyo Pharma Company Profile 2024: Valuation, …
Joyo Pharma General Information Description. Developer of new drugs designed for treatment of tumor, autoimmunity, metabolism and infectious diseases. The company's drugs take translational and clinical medicine as the core and …See details»
Joyo Pharma - Funding, Financials, Valuation & Investors
Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.See details»
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
May 16, 2024 Under the terms of the ERAS-0015 license agreement, in exchange for an exclusive license to develop and commercialize ERAS-0015 in the Erasca territory (worldwide, …See details»
Guangzhou JOYO Pharma Company - PitchBook
Information on valuation, funding, acquisitions, investors, and executives for Guangzhou JOYO Pharma Company. Use the PitchBook Platform to explore the full profile.See details»
JOYO PHARMA complete pre-C round of financing - PharmArch.com
Jun 8, 2023 JOYO PHARMA follows the philosophy of “In China, for Global” and focuses on tumors, autoimmunity, metabolism and infectious diseases. JOYO PHARMA has a number of …See details»
Guangzhou Joyo Pharma | ApexOnco - Clinical Trials news and …
Dec 18, 2023 The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo. Read more. Trial results. 18 December 2023. ... Subscribe to Guangzhou Joyo …See details»
Joyo Pharma - Crunchbase
Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.See details»
Chinese pharma firms Joyo, Zion secure Series B funding
Jul 28, 2021 Chinese pharma firms Joyo, Zion secure Series B funding. Photo: Getty Images Pro via DealStreetAsia. Liya Su. 28 July, 2021. Joyo Pharma has secured over 300 million …See details»
Sufenidone-Guangzhou-JOYO-Pharma - AdisInsight - Springer
Nov 24, 2023 14 Jan 2023 Guangzhou JOYO Pharma completes a phase I trial in Idiopathic pulmonary fibrosis (In volunteers) in China (PO) ( NCT06135363) You need to be a logged in …See details»
Erasca doubles down on RAS | ApexOnco - Clinical …
May 17, 2024 Remarkably, the Joyo deal is at least the eighth transaction Erasca has struck to bring in R&D assets since it was founded in 2018, but most have now fallen by the wayside. This now includes the clinical-stage ERK1/2 …See details»
Erasca trims workforce and pipeline to focus on KRAS and …
May 17, 2024 Erasca has announced a shakeup of its clinical pipeline, shutting down three clinical programmes and licensing two cancer therapies from Joyo Pharmatech and Medshine …See details»
Series C - Joyo Pharma - 2023-06-07 - Crunchbase
Jun 7, 2023 Series C - Joyo Pharma . Save . Summary. Overview. Edit Overview Section. Organization Name . Joyo Pharma . Announced Date Jun 7, 2023; Funding Type Series C; …See details»
Erasca lays off 18%, swaps out KRAS program for fresh options
May 17, 2024 It's not the only licensing deal Erasca announced yesterday evening. The company is also handing over $12.5 million to Joyo Pharmatech for the ex-China rights to a …See details»
Erasca cuts staff and projects to prioritize KRAS and ... - Patsnap
Jun 27, 2024 Erasca has recently announced significant changes to its clinical pipeline, ceasing operations for three clinical programs and acquiring two cancer therapies from Joyo …See details»
Erasca Announces Strategic In-Licensing of RAS Mutation …
May 20, 2024 Under the license agreement, in exchange for an exclusive license to develop and commercialize ERAS-0015 in the Erasca territory (worldwide, excluding mainland China, Hong …See details»
Erasca In-licenses Two China RAS Candidates in Two Deals Worth …
May 17, 2024 San Diego’s Erasca acquired rights for two China-developed pre-clinical RAS candidates in two separate agreements, while it is sidelining two of its own candidates and …See details»
Joyo Pharma - Updates, News, Events, Signals & Triggers
Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.See details»
Sudapyridine (WX-081) | Working Group for New TB Drugs
WX-081 is under investigation in a phase 2 study in patients." And from the Shanghai Jiatan Biotech Ltd., a subsidiary of Guangzhou JOYO Pharma Ltd., Shanghai, China the following …See details»
Series B - Joyo Pharma - 2021-07-28 - Crunchbase
Jul 28, 2021 Joyo Pharma raised $46218552 on 2021-07-28 in Series B. SDIC Venture Capital SDIC Venture Capital is a fund management company founded by the State Development and …See details»
Pharma 4.0™: Case Studies and Lessons Learned
1 day ago As the pharmaceutical industry navigates the complexities of digital transformation, the concept of Pharma 4.0™ emerges as a pivotal framework for integrating advanced …See details»